USANA Health Sciences Q4 Earnings Exceed Expectations
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 2 days ago
0mins
Should l Buy USNA?
Source: seekingalpha
- Earnings Beat: USANA Health Sciences reported a Q4 non-GAAP EPS of $0.60, surpassing expectations by $0.19, indicating a significant improvement in profitability that boosts investor confidence.
- Stable Revenue Growth: The company achieved Q4 revenue of $226.2 million, a 5.7% year-over-year increase, exceeding expectations by $240,000, which demonstrates its strengthening competitive position in the market and potential for future growth.
- Optimistic Outlook: USANA expects fiscal 2025 net sales to exceed guidance, reflecting management's confidence in future performance, which may attract more investor interest in its long-term prospects.
- Increased Market Attention: Although the company is on a “turnaround watch list,” analysts suggest its current valuation is not yet compelling, indicating a cautious market sentiment regarding its future performance.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy USNA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on USNA
Wall Street analysts forecast USNA stock price to rise
1 Analyst Rating
0 Buy
1 Hold
0 Sell
Hold
Current: 19.000
Low
39.00
Averages
39.00
High
39.00
Current: 19.000
Low
39.00
Averages
39.00
High
39.00
About USNA
USANA Health Sciences, Inc. and subsidiaries is a global nutrition, personal health and wellness company that develops and manufactures science-based nutritional and personal care products. Its segments include Direct selling and Hiya direct-to-consumer. The Direct Selling segment develops and manufactures science-based nutritional, personal care and skincare products with a primary focus on promoting long-term health and wellness in various geographic markets worldwide that are distributed through the direct selling channel. The Hiya direct-to-consumer segment is a provider of children’s health and wellness products in the United States that are distributed through the direct-to-consumer channel. Its product line includes USANA Nutritionals Optimizers, Essentials/CellSentials, and Foods. USANA Nutritionals Optimizers products include Proflavanol, CoQuinone 30, and BiOmega-3. Essentials/CellSentials products include USANA CellSentials and HealthPak 100.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
USANA Health Sciences Q4 2025 Earnings Call Insights
- Strategic Focus Shift: CEO Kevin Guest's return emphasizes a renewed commitment to six strategic priorities, including enhancing brand positioning and product innovation, indicating management's confidence in driving sustainable growth.
- Sales Growth Outlook: The company projects a 4% midpoint growth in net sales for fiscal 2026, primarily driven by the expansion of Rise Wellness and Hiya, reflecting management's positive outlook on market demand and execution capabilities.
- Inventory Management Challenges: CFO G. Hekking reported an increase in inventory to $107 million, up 48% year-over-year, mainly to support the expansion needs of Rise Wellness and Hiya, showcasing the company's flexibility and foresight in responding to market changes.
- Investment in Technology and Innovation: Management emphasized ongoing investments in technology modernization and product innovation to enhance customer experience and sales momentum, indicating the company's strategy to seek differentiation in the competitive nutrition industry.
See More
USANA (USNA) Q4 2025 Earnings Call Transcript
See More
USANA Health Sciences Q4 Earnings Exceed Expectations
- Earnings Beat: USANA Health Sciences reported a Q4 non-GAAP EPS of $0.60, surpassing expectations by $0.19, indicating a significant improvement in profitability that boosts investor confidence.
- Stable Revenue Growth: The company achieved Q4 revenue of $226.2 million, a 5.7% year-over-year increase, exceeding expectations by $240,000, which demonstrates its strengthening competitive position in the market and potential for future growth.
- Optimistic Outlook: USANA expects fiscal 2025 net sales to exceed guidance, reflecting management's confidence in future performance, which may attract more investor interest in its long-term prospects.
- Increased Market Attention: Although the company is on a “turnaround watch list,” analysts suggest its current valuation is not yet compelling, indicating a cautious market sentiment regarding its future performance.
See More
USANA Health Sciences Set to Release Q4 Earnings
- Earnings Announcement: USANA Health Sciences is set to announce its Q4 2023 earnings on February 16 after market close, with consensus EPS estimate at $0.41, reflecting a 35.9% year-over-year decline, while revenue is expected to reach $225.96 million, indicating a 5.6% year-over-year increase.
- Historical Performance: Over the past two years, USANA has surpassed EPS estimates 75% of the time and revenue estimates 63% of the time, demonstrating a degree of stability and adaptability in its financial performance amidst market fluctuations.
- Estimate Revisions: In the last three months, there has been one upward revision for EPS estimates with no downward adjustments, and similarly, revenue estimates have seen one upward revision, suggesting increased market confidence in USANA's future performance.
- Future Outlook: USANA anticipates that net sales for fiscal 2025 will exceed guidance, indicating a positive outlook for growth, although the company is currently viewed as not being a bargain investment opportunity.
See More
Functional Food Market Projected to Reach $438 Billion by 2026
- Market Size Projection: The global functional food and beverage market is projected to reach approximately $438 billion by 2026, expanding at an annual rate of 10.65%, indicating a significant consumer shift away from conventional delivery formats.
- New Product Launch: Doseology Sciences recently initiated pilot production of caffeine-based energy pouches in January 2026, marking the Feed That Brain brand's entry into the rapidly growing oral pouch category, which is expected to attract demand for portable alternatives.
- Strategic Acquisition: Doseology Sciences acquired the Feed That Brain brand for $400,000 in August 2025, fully paid through stock issuance, aiming to leverage its strengths in functional product design to drive new product commercialization.
- Market Trend Support: The global energy drinks market is expected to grow from $79.4 billion in 2024 to $125.1 billion by 2030, reflecting rising consumer demand for alternative caffeine delivery methods, which further supports Doseology's market strategy.
See More
Self-Renewal Day: Leadership and Growth Insights
- Significance of Self-Renewal Day: February 2 is designated as Self-Renewal Day, aimed at prompting business leaders to reassess strategies and personal development, emphasizing that sustained corporate success begins with leaders' commitment to self-breakthroughs.
- Choices of Leaders: USANA CEO Kevin Guest shares his experience of walking away from his dream of being a full-time musician to pursue leadership and service, illustrating that true self-renewal requires courage and a focus on long-term values.
- Necessity of Transformation: Guest emphasizes that modern executives must break free from familiar patterns and face challenges to achieve genuine transformation and growth, highlighting that stagnation is the enemy of progress.
- Six Concrete Steps: Guest outlines six specific steps for leaders looking to elevate their performance, encouraging them to transform Self-Renewal Day into a catalyst for long-term strategic growth, stressing the importance of intentional action.
See More
USANA Health Sciences Q4 2025 Earnings Call Insights
- Strategic Focus Shift: CEO Kevin Guest's return emphasizes a renewed commitment to six strategic priorities, including enhancing brand positioning and product innovation, indicating management's confidence in driving sustainable growth.
- Sales Growth Outlook: The company projects a 4% midpoint growth in net sales for fiscal 2026, primarily driven by the expansion of Rise Wellness and Hiya, reflecting management's positive outlook on market demand and execution capabilities.
- Inventory Management Challenges: CFO G. Hekking reported an increase in inventory to $107 million, up 48% year-over-year, mainly to support the expansion needs of Rise Wellness and Hiya, showcasing the company's flexibility and foresight in responding to market changes.
- Investment in Technology and Innovation: Management emphasized ongoing investments in technology modernization and product innovation to enhance customer experience and sales momentum, indicating the company's strategy to seek differentiation in the competitive nutrition industry.
See More
USANA (USNA) Q4 2025 Earnings Call Transcript
See More
USANA Health Sciences Q4 Earnings Exceed Expectations
- Earnings Beat: USANA Health Sciences reported a Q4 non-GAAP EPS of $0.60, surpassing expectations by $0.19, indicating a significant improvement in profitability that boosts investor confidence.
- Stable Revenue Growth: The company achieved Q4 revenue of $226.2 million, a 5.7% year-over-year increase, exceeding expectations by $240,000, which demonstrates its strengthening competitive position in the market and potential for future growth.
- Optimistic Outlook: USANA expects fiscal 2025 net sales to exceed guidance, reflecting management's confidence in future performance, which may attract more investor interest in its long-term prospects.
- Increased Market Attention: Although the company is on a “turnaround watch list,” analysts suggest its current valuation is not yet compelling, indicating a cautious market sentiment regarding its future performance.
See More
USANA Health Sciences Set to Release Q4 Earnings
- Earnings Announcement: USANA Health Sciences is set to announce its Q4 2023 earnings on February 16 after market close, with consensus EPS estimate at $0.41, reflecting a 35.9% year-over-year decline, while revenue is expected to reach $225.96 million, indicating a 5.6% year-over-year increase.
- Historical Performance: Over the past two years, USANA has surpassed EPS estimates 75% of the time and revenue estimates 63% of the time, demonstrating a degree of stability and adaptability in its financial performance amidst market fluctuations.
- Estimate Revisions: In the last three months, there has been one upward revision for EPS estimates with no downward adjustments, and similarly, revenue estimates have seen one upward revision, suggesting increased market confidence in USANA's future performance.
- Future Outlook: USANA anticipates that net sales for fiscal 2025 will exceed guidance, indicating a positive outlook for growth, although the company is currently viewed as not being a bargain investment opportunity.
See More
Functional Food Market Projected to Reach $438 Billion by 2026
- Market Size Projection: The global functional food and beverage market is projected to reach approximately $438 billion by 2026, expanding at an annual rate of 10.65%, indicating a significant consumer shift away from conventional delivery formats.
- New Product Launch: Doseology Sciences recently initiated pilot production of caffeine-based energy pouches in January 2026, marking the Feed That Brain brand's entry into the rapidly growing oral pouch category, which is expected to attract demand for portable alternatives.
- Strategic Acquisition: Doseology Sciences acquired the Feed That Brain brand for $400,000 in August 2025, fully paid through stock issuance, aiming to leverage its strengths in functional product design to drive new product commercialization.
- Market Trend Support: The global energy drinks market is expected to grow from $79.4 billion in 2024 to $125.1 billion by 2030, reflecting rising consumer demand for alternative caffeine delivery methods, which further supports Doseology's market strategy.
See More
Self-Renewal Day: Leadership and Growth Insights
- Significance of Self-Renewal Day: February 2 is designated as Self-Renewal Day, aimed at prompting business leaders to reassess strategies and personal development, emphasizing that sustained corporate success begins with leaders' commitment to self-breakthroughs.
- Choices of Leaders: USANA CEO Kevin Guest shares his experience of walking away from his dream of being a full-time musician to pursue leadership and service, illustrating that true self-renewal requires courage and a focus on long-term values.
- Necessity of Transformation: Guest emphasizes that modern executives must break free from familiar patterns and face challenges to achieve genuine transformation and growth, highlighting that stagnation is the enemy of progress.
- Six Concrete Steps: Guest outlines six specific steps for leaders looking to elevate their performance, encouraging them to transform Self-Renewal Day into a catalyst for long-term strategic growth, stressing the importance of intentional action.
See More
